802 terminated. 802 Phase 2, 122 Phase 1, 114 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 802 | Terminated 802 |
| Phase 1 | 122 | Terminated 122 |
| Phase 3 | 114 | Terminated 114 |
Follow Infections: new trials by email Literature Review of Infections trials Research Report on Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections pathogen-specific CTLs - Pathogen Infection, EBV Infection | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2026-06-01 | 2026-08-24 |
| Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection SNG001, Placebo - Viral Pneumonia | Phase 2 | Terminated | Synairgen Research Ltd. | 11 | 2025-09-02 | 2026-09-14 |
| Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) 225Ac-SSO110 + SoC, Atezolizumab, Durvalumab - Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Ariceum Therapeutics GmbH | 2 | 2025-07-01 | 2026-02-05 |
| Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection Obeldesivir, Obeldesivir Placebo - RSV Infection | Phase 2 | Terminated | Gilead Sciences | 4 | 2025-03-05 | 2026-06-08 |
| Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment - Chronic Urticaria, Idiopathic, Hidradenitis | Phase 2 | Terminated | InflaRx GmbH | 73 | 2025-01-02 | 2026-02-03 |
| A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) Brensocatib, Placebo - Hidradenitis Suppurativa | Phase 2 | Terminated | Insmed Incorporated | 214 | 2024-12-16 | 2026-06-29 |
| The Clostridioides Difficile Trial of REC-3964 REC-3964 - Recurrent Clostridioides Difficile Infection | Phase 2 | Terminated | Recursion Pharmaceuticals Inc. | 3 | 2024-10-14 | 2025-11-17 |
| Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection Obeldesivir, Obeldesivir Placebo - RSV Infection | Phase 2 | Terminated | Gilead Sciences | 150 | 2024-10-14 | 2026-06-30 |
| Evaluating Emetine for Viral Outbreaks (EVOLVE) Emetine Hydrochloride, Placebo - COVID-19 | Phase 2 / Phase 3 | Terminated | Johns Hopkins University | 4 | 2024-05-15 | 2026-01-23 |
| A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab Spesolimab, Placebo - Hidradenitis Suppurativa (HS) | Phase 2 / Phase 3 | Terminated | Boehringer Ingelheim | 39 | 2024-05-08 | 2026-06-17 |
| A Controlled Human Rhinovirus Infection Study of 2-Deoxy-D-Glucose in Healthy Adults 2-Deoxy-D-glucose, Placebo - Acute Nasopharyngitis | Phase 2 | Terminated | G.ST Antivirals GmbH | 64 | 2024-04-02 | 2024-11-19 |
| CX-4945 in Viral Community Acquired Pneumonia CX-4945 (SARS-CoV-2 domain), Placebo (SARS-CoV-2 domain), CX-4945 (Influenza virus domain) - Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia | Phase 2 | Terminated | Senhwa Biosciences, Inc. | 45 | 2024-03-20 | 2026-01-08 |
| Study of Obeldesivir in Children and Adolescents With COVID-19 Obeldesivir - COVID-19 | Phase 2 / Phase 3 | Terminated | Gilead Sciences | 3 | 2023-12-26 | 2025-02-03 |
| A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1 VH3739937, Placebo - HIV Infections | Phase 2 | Terminated | ViiV Healthcare | 21 | 2023-12-21 | 2025-10-20 |
| A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection Sisunatovir, Placebo - Respiratory Syncytial Virus Infection | Phase 2 / Phase 3 | Terminated | Pfizer | 16 | 2023-12-08 | 2025-11-10 |
| Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS). Deucravacitinib, Placebo - Hidradenitis Suppurativa | Phase 2 | Terminated | Beth Israel Deaconess Medical Center | 7 | 2023-11-30 | 2026-05-29 |
| Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation Pregabalin, Independent walking training, Placebo - Chronic Fatigue Syndrome, COVID-19, Long Haul | Phase 2 | Terminated | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | 23 | 2023-10-24 | 2026-06-17 |
| Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS) Methylprednisolone - Post-COVID-19 Syndrome | Phase 2 | Terminated | Charite University, Berlin, Germany | 96 | 2023-10-01 | 2026-05-05 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa SAR444656 (KT-474), Placebo - Hidradenitis Suppurativa | Phase 2 | Terminated | Sanofi | 70 | 2023-09-29 | 2025-12-11 |
| Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly Comirnaty - Vaccination; Infection, COVID-19 | Phase 2 | Terminated | Radboud University Medical Center | 48 | 2023-09-26 | 2024-03-28 |
Showing 20 of 802. Sign in to see all of them.
COVID-19 (242) · HIV Infections (76) · Coronavirus Infections (62) · Burkitt Lymphoma (52) · Hepatitis C (33) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (33) · Lymphoma, Large B-Cell, Diffuse (30) · Pneumonia (27) · Acquired Immunodeficiency Syndrome (26) · Hepatitis B, Chronic (26) · Lymphoma, Non-Hodgkin (26) · Lymphoma, Mantle-Cell (25) · Lymphoma, Follicular (24) · Hepatitis B (23)
Virus Diseases (565) · RNA Virus Infections (424) · Respiratory Tract Diseases (325) · Respiratory Tract Infections (292) · Lung Diseases (290) · Coronaviridae Infections (254) · Nidovirales Infections (254) · Pneumonia (238) · Pneumonia, Viral (237) · Pathological Conditions, Signs and Symptoms (217) · Pathologic Processes (198) · Coronavirus Infections (193) · Communicable Diseases (180) · Immune System Diseases (170)
Standard of Care (29) · Sodium Chloride (24) · Rituximab (23) · Hydroxychloroquine (20) · Saline Solution (20) · Azithromycin (18) · Tenofovir (18) · Cyclophosphamide (14) · Ribavirin (14) · Ritonavir (14) · Methotrexate (13) · entecavir (12) · Cytarabine (11) · Vancomycin (11) · Radiotherapy (10)
National Institute of Allergy and Infectious Diseases (NIAID) (24) · Pfizer (17) · Merck Sharp & Dohme LLC (14) · M.D. Anderson Cancer Center (12) · GlaxoSmithKline (10) · Novartis Pharmaceuticals (10) · ViiV Healthcare (10) · Gilead Sciences (8) · Johns Hopkins University (8) · National Cancer Institute (NCI) (8) · Boehringer Ingelheim (7) · Fred Hutchinson Cancer Center (7) · Revimmune (7) · Arrowhead Pharmaceuticals (6) · Bristol-Myers Squibb (6)
United States (454) · Canada (77) · Spain (72) · France (70) · Germany (66) · United Kingdom (59) · Italy (47) · Brazil (43) · Australia (34) · Poland (34) · South Africa (34) · Belgium (32) · South Korea (32) · Argentina (24) · China (23)
David R Strayer, MD (3) · Elias Jabbour (3) · Hyo Suk Lee, M.D., Ph.D. (3) · Ajay Gopal (2) · Aude Chapuis (2)
PMID 34473343, PMID 32031570, PMID 39903535, PMID 32171076, PMID 35244208, PMID 29515037, PMID 34658014, PMID 41671463, PMID 23053510, PMID 26908786, PMID 28472957, PMID 31108015, PMID 32788708, PMID 33570583, PMID 35622074, PMID 10722036, PMID 1138591, PMID 11502226, PMID 12454520, PMID 12545007, PMID 12700374, PMID 15030519, PMID 15155205, PMID 15199325, PMID 15885816, PMID 1607900, PMID 16570523, PMID 16628625, PMID 16962381, PMID 17276373, PMID 17919105, PMID 18230259, PMID 18353115, PMID 18434652, PMID 18752857, PMID 18946659, PMID 19139736, PMID 19190233, PMID 19234342, PMID 19569973, PMID 19833404, PMID 20186346, PMID 20332511, PMID 20453627, PMID 20459801, PMID 20463812, PMID 20607114, PMID 20636279, PMID 20646908, PMID 20844049
2018 (9), 2023 (9), 2016 (8), 2014 (6), 2015 (5), P30CA015704 (5), 2019 (4), P30CA016672 (4), U01AI068636 (4), 2009 (3), 2017 (3), 2008 (2), P30CA015083 (2), U01AI068632 (2), 1UG3DE030401-01 (1)